News
Combo treatment under review for Waldenstrom macroglobulinemia
The FDA has granted priority review to the combination of ibrutinib plus rituximab.
News
Hemophilia adherence tied to perception of disease
Adherence to prophylaxis is generally high, but quality of life and disease coping matter.
News
British good practice paper offers MCL diagnosis pearls
The good practice paper includes new information on pathology and use of PET/CT scanning in staging of disease.
News
Emicizumab gets priority review for hemophilia A without inhibitors
The Food and Drug Administration is expected to make an approval decision on emicizumab in October 2018.
News
FDA grants priority review to first-line SAA treatment
Eltrombopag is being evaluated for first-line treatment of severe aplastic anemia with standard immunosuppressive therapy.
News
Overcoming TP53 mutation proves difficult in MCL
A new study shows disappointing results for the addition of lenalidomide to chemoimmunotherapy regimens.
News
CAR T therapy to enter early testing in multiple myeloma
The phase 1b/2 trial will begin enrollment in the second half of 2018.
News
FDA to review FLT3 agent for refractory AML
The Food and Drug Administration has granted priority review to Astellas Pharma’s gilteritinib.
News
FDA approves epoetin alfa biosimilar to treat anemia
This is the first product approved as biosimilar to epoetin alfa.
News
Study: No link between non-Hodgkin lymphoma and Q fever
The study looks at the incidence of non-Hodgkin lymphoma in the Netherlands before, during, and after a Q fever epidemic.
News
FDA approves anti-CD38 with VMP in myeloma
The FDA approved the drug in combination with VMP for patients who are ineligible for transplant.
News
FDA places partial hold on trials after secondary lymphoma
A pediatric patient developed a secondary T-cell lymphoma during a phase 1 trial of tazemetostat.
News
FDA approves new drug for thrombocytopenia
The oral spleen tyrosine kinase inhibitor is expected to be available in the United States in late May.
News
PDPK1 could be novel target in MCL
The poor prognosis of mantle cell lymphoma despite advances in immunochemotherapy means that new therapeutic targets are needed.
News
FDA grants priority review of follicular lymphoma drug
The target date for FDA action is Oct. 5, 2018.